XML 50 R19.htm IDEA: XBRL DOCUMENT
v3.26.1

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2025
Income Tax Disclosure [Abstract] |
Income Taxes | Note 11 - Income Taxes
| A. | Tax rates
Ordinary taxable income in Israel is subject to a corporate tax rate of 23%. Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold. The Company’s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws. Chemomab Inc. is subject to a federal flat income tax rate of 21% and state income taxes as applicable.
| B. | Tax assessments
As of December 31, 2025, the Company’s tax assessments are considered final up to and including the following years: the tax assessment of Chemomab Ltd. for the year ended December 31, 2020, and the tax assessments of Chemomab Therapeutics Ltd. and Chemomab Therapeutics Israel Ltd. for the year ended December 31, 2019.
| C. | Losses for tax purposes carried forward in future years
As of December 31, 2025 and 2024, the Company and its subsidiaries had net operating loss carryforwards of approximately $192 million and $176 million, respectively, which may be carried forward indefinitely to offset future taxable income, subject to applicable tax regulations in the relevant jurisdictions.
| D. | Deferred taxes
|  | In respect of:
|  | December 31, |  |  | December 31, |
|  | 2025 |  |  | 2024
|  | USD thousands |  |  | USD thousands |
Net operating loss carryforward |  |  | 44,464 |  |  |  | *40,755 |
Capital losses |  |  | 3,271 |  |  |  | - |
Share-based compensation expense |  |  | 374 |  |  |  | 351 |
Capitalized research and development costs |  |  | 1,742 |  |  |  | 3,103 |
Other |  |  | 8 |  |  |  | 10 |
Deferred tax assets |  |  | 49,859 |  |  |  | 44,219 |
Less - valuation allowance |  |  | (49,859 | ) |  |  | (44,219 | )
Net deferred tax assets, net of valuantion allowance |  |  | - |  |  |  | - |
*This excludes capital losses of approximately $14,223 thousands for which the Company has recorded a full valuation allowance. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is more likely than not that deferred tax assets will not be realized. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2025 and 2024 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The Company realized a benefit of deferred tax assets in 2025 in the amount of $544 thousand which was offset by a valuation allowance.
| E. | Roll forward of valuation allowance
|  | USD thousands |
Balance at December 31, 2022 |  | $ | 41,195 |
Currency translation Income |  |  | (3,295 | )
Increase in valuation allowance |  |  | 5,571 |
Balance at December 31, 2023 |  | $ | 43,471 |
Currency translation Income |  |  | (2,459 | )
Increase in valuation allowance |  |  | 3,207 |
Balance at December 31, 2024 |  |  | 44,219 |
Increase in valuation allowance for capital losses |  |  | 3,271 |
Increase in valuation allowance |  |  | 2,916 |
Decrease in valuation allowance |  |  | (547 | )
Net increase during the year |  |  | 5,640 |
Balance at December 31, 2025 |  |  | 49,859 |
| F. | Reconciliation of theoretical income tax expense to actual income tax expense
A reconciliation of the Company’s theoretical income tax expense at the Israeli statutory income tax rate, the income tax rate in our country of tax domicile, to actual income tax expense is as follows:
|  | 2025 Amount |  |  | % |
Israeli statutory income tax rate |  |  | (2,069 | ) |  |  | 23.0 | %
Nontaxable income or nondeductible expenses: |  |  |  |  |  |  |  |
Share-based compensation |  |  | 120 |  |  |  | (1.3 | )%
Other |  |  | 5 |  |  |  | (0.1 | )%
Change in valuation allowance |  |  | 2,297 |  |  |  | (25.5 | )%
Other |  |  | (344 | ) |  |  | 3.8 | %
Foreign tax effects |  |  | (9 | ) |  |  | 0.1 | %
Actual income tax expenses |  |  | - |  |  |  | 0.0 | %
|  | December 31, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
|  | USD thousands |  |  | USD thousands |
Loss before income taxes |  |  | (13,945 | ) |  |  | (24,221 | )
Statutory tax rate |  |  | 23 | % |  |  | 23 | %
Theoretical tax benefit |  |  | (3,207 | ) |  |  | (5,571 | )
Change in temporary differences for which deferred taxes were not recognized |  |  | 858 |  |  |  | (1,177 | )
Tax rate differential |  |  | 9 |  |  |  | 10 |
Non-deductible expenses |  |  | 148 |  |  |  | 346 |
Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards |  |  | 2,192 |  |  |  | 6,392 |
Actual income tax expense (Benefit) |  |  | - |  |  |  | - |
| G. | Income (Loss) Before Income Taxes by Jurisdiction
In respect of:
|  | 2025 |  |  | 2024 |  |  | 2023 |
|  | USD thousands |  |  | USD thousands |  |  | USD thousands |
Israel |  |  | (9,035 | ) |  |  | (13,925 | ) |  |  | (23,534 | )
Foreign |  |  | 40 |  |  |  | (20 | ) |  |  | (687 | )
Total |  |  | (8,995 | ) |  |  | (13,945 | ) |  |  | (24,221 | )
| H. | Accounting for uncertainty in income taxes
As of December 31, 2025, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company’s accounting policy is to accrue interest and penalties related to income taxes as a component of income tax expense.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 740 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 740 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration